SANGUINATE™

Phase 2Biologic

PProlong Pharmaceuticals

SANGUINATE™ is one of 148 biologic programs targeting Kidney Transplant. It is currently in Phase 2.

Indications

Total Trials

Active Trials

147

Competitors

Pipeline

Status by Indication[3][1]

Indication

Kidney TransplantActive, not recruiting

AnemiaActive, not recruiting

Sickle Cell DiseaseActive, not recruiting

Subarachnoid HemorrhageActive, not recruiting

Kidney TransplantPhase 2/Phase 3

Active, not recruiting

AnemiaPhase 1

Active, not recruiting

Sickle Cell DiseasePhase 2

Active, not recruiting

Subarachnoid HemorrhagePhase 2

Active, not recruiting

Competition

Competitive Landscape

476 competitors in Kidney Transplant

#DrugCompanyPhaseTrials

Simulect

Novartis

Preclinical

15 2

Medrol

Pfizer

Preclinical

12 3

SANGUINATE™

PProlong Pharmaceuticals

Phase 2

2 4

Zinbryta

Roche

Preclinical

6 5

Zemplar

AbbVie

Preclinical

2 6

Radicava

Shionogi

Preclinical

1 7

Cysteine Hydrochloride

Novartis

Preclinical

1 8

Sensipar

Amgen

Preclinical

1 9

Epogen

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Preclinical

1 10

Precedex

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Sickle Cell Disease3 trials

Study of SANGUINATE™ Versus Hydroxyurea in Sickle Cell Disease (SCD) Patients

Completed·PProlong Pharmaceuticals·Phase 1·NCT01848925·24 enrolled

Study of SANGUINATE™ In the Treatment of Sickle Cell Disease Patients With Vaso-Occlusive Crisis

Completed·PProlong Pharmaceuticals·Phase 2·NCT02411708·24 enrolled

SANGUINATE™ in Sickle Cell Disease Associated Leg Ulcer

Completed·PProlong Pharmaceuticals·Phase 2·NCT02600390·10 enrolled

Kidney Transplant2 trials

Efficacy and Safety of SANGUINATE™ for Reduction of Delayed Graft Function in Patients Receiving a Kidney Transplant

Completed·PProlong Pharmaceuticals·Phase 2/3·NCT02490202·60 enrolled

A Study on SANGUINATE™ for the Reduction of Delayed Graft Function in Kidney Transplant Patients

Withdrawn·PProlong Pharmaceuticals·Phase 2·NCT02658162

Anemia1 trial

A Phase 1 Safety Study of SANGUINATE™ In Patients With Acute Severe Anemia.

Completed·PProlong Pharmaceuticals·Phase 1·NCT02754999·103 enrolled

Subarachnoid Hemorrhage1 trial

Safety and Effect of SANGUINATE™ Infusion in Patients at Risk of Delayed Cerebral Ischemia (DCI) Following Subarachnoid Hemorrhage (SAH)

Completed·PProlong Pharmaceuticals·Phase 2·NCT02323685·12 enrolled

Tics1 trial

An Assessment of the Safety and Pharmacokinetics of Ascending Doses of SANGUINATE™ in Healthy Volunteers.

Terminated·PProlong Pharmaceuticals·Phase 1·NCT01847222·2 enrolled

1 more indication

End-Stage Renal Disease1 trial

Study to Assess the Safety and Impact on Humoral Sensitization of SANGUINATE in Patients With End Stage Renal Disease

Completed·PProlong Pharmaceuticals·Phase 1·NCT02437422·5 enrolled

Sources

References

[1]
ClinicalTrials.gov — 9 trial records for SANGUINATE™. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — SANGUINATE™ compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for SANGUINATE™. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Prolong Pharmaceuticals company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 2[1]
Company: PProlong Pharmaceuticals

SANGUINATE™

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Sickle Cell Disease3 trials

Kidney Transplant2 trials

Anemia1 trial

Subarachnoid Hemorrhage1 trial

Tics1 trial

End-Stage Renal Disease1 trial

References

Drug Info

Quick Facts

Related News